Is Colorado Drug Investigators Association Legit?

The Colorado Drug Investigators Association (CDIA) demonstrates a mixed financial picture. While the organization consistently reports zero liabilities and no officer compensation, indicating good financial hygiene and a volunteer-driven leadership, its financial stability has fluctuated. In 2023, expenses significantly outpaced revenue ($248,021 vs. $180,723), leading to a substantial decrease in assets from $139,114 in 2022 to $71,786. This recent deficit spending is a concern, especially following a period of growth in 2022 where revenue exceeded expenses. The organization's transparency is strong, with consistent IRS 990 filings and clear reporting of no liabilities and no executive compensation. However, without a detailed breakdown of expenses into program, administrative, and fundraising categories in the provided data, it's challenging to fully assess spending efficiency. The NTEE code B60 (Law Enforcement Associations) suggests a focus on professional development and advocacy, which typically involves program activities like training and conferences. The lack of reported officer compensation is a positive indicator of resources being directed towards the mission rather than high executive salaries. Overall, CDIA appears to be a transparent organization with a volunteer leadership structure. However, the recent financial performance, particularly the significant deficit in 2023, warrants closer monitoring. Its ability to manage expenses and maintain asset levels will be crucial for its long-term sustainability and mission delivery. The historical data shows periods of both surplus and deficit, suggesting a need for more consistent financial planning to avoid large swings in asset levels.